| Overcoming castration resistance in prostate cancer. | |
| | |
MedLine Citation:
|
PMID: 22472508 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
PURPOSE OF REVIEW: Recent advances in our understanding of the androgen axis signaling pathway have led to the development of therapeutic strategies to overcome the state of 'castration resistance' in prostate cancer. In this review, we examine the mechanisms of castration resistance, as well as recently reported and ongoing clinical studies, which will further identify therapeutic opportunities for novel therapeutics targeting the androgen-signaling axis in advanced prostate cancer. RECENT FINDINGS: As evidenced by recently reported positive phase III clinical trials, secondary hormonal agents such as abiraterone and MDV3100 may still be very effective in the treatment of castration-resistant prostate cancer, even after the use of docetaxel chemotherapy. SUMMARY: Novel agents targeting this pathway have demonstrated a proof of principle that overcoming castration resistance is possible, leading to significant changes in the landscape of treatment in this disease. The optimal combination, sequence, and pattern of use in these novel therapies will be the focus of clinical research in the near future. |
| | |
Authors:
|
Che-Kai Tsao; Alexander C Small; Matthew D Galsky; William K Oh |
Related Documents
:
|
9498898 - Aromatic amines and cancer. 16130488 - Estimation of genetic parameters for lactational milk yields using two-dimensional rand... 10810108 - Prevalence and pattern of occupational exposure to whole body vibration in great britai... 22527168 - A cross-sectional analysis of the association between diet and insulin-like growth fact... 19827868 - Survival of ovarian cancer in iran: 2000-2004. 23054008 - Association of muc6-minisatellite variants with susceptibility to rectal carcinoma. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Current opinion in urology Volume: 22 ISSN: 1473-6586 ISO Abbreviation: Curr Opin Urol Publication Date: 2012 May |
Date Detail:
|
Created Date: 2012-04-04 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9200621 Medline TA: Curr Opin Urol Country: United States |
Other Details:
|
Languages: eng Pagination: 167-74 Citation Subset: IM |
Affiliation:
|
Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, New York, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Infant feeding practices at routine PMTCT sites, South Africa: results of a prospective observationa...
Next Document: Novel agents for the management of castration-resistant prostate cancer.